Wellness Education
Lean Body
GLP-1, GIP, and glucagon receptor agonists represent the most significant advance in metabolic medicine. These peptides work by mimicking natural gut hormones to regulate appetite, blood sugar, and fat metabolism.
22%
Average body weight reduction with Tirzepatide
24%
Greater weight loss vs. single-agent therapies
~40%
Reduction in hunger signaling via hypothalamic pathways
How They Work
These peptides bind to receptors in the gut, brain, and pancreas to reduce hunger signals, slow gastric emptying, stimulate insulin release, and promote fat breakdown. Triple agonists like Retatrutide additionally activate glucagon receptors to further increase daily caloric burn and support lean mass preservation.
Key Benefits
Appetite Control
Reduces hunger signals by up to 40% through hypothalamic pathways
Fat Loss
Clinical trials show 15-22% total body weight reduction
Blood Sugar
Improves insulin sensitivity and fasting glucose
Cardiovascular
Emerging data shows reduction in heart attacks and stroke risk
Lean Body Category
7 compounds in this category
Browse all compounds →Educational Content. Category content is for informational purposes only. Not intended as medical advice, diagnosis, or treatment.
Compounds in Lean Body
7 compoundsTirzepatide
Dual GIP/GLP-1 Agonist
- Superior to single-agent therapies in every trial
- Activates two incretin pathways for broader metabolic impact
Reference Codes
[TR20]20mg[TR40]40mgRetatrutide
Triple GLP-1/GIP/Glucagon Agonist
- Broadest receptor pathway activation — 3 mechanisms at once
- Enhances daily energy expenditure and lean mass preservation
Reference Codes
[RT20]20mg[RT30]30mgSemaglutide
GLP-1 Receptor Agonist
- Most-studied GLP-1 agonist with over 10,000 participants across STEP trials
- Demonstrated cardiovascular benefit independent of weight loss
Reference Codes
[SM5]5mg[SM10]10mg[SM15]15mg[SM20]20mg[SM30]30mgAOD-9604
HGH Fragment 177-191
- Isolates the fat-loss mechanism of growth hormone without systemic side effects
- Granted GRAS status by the FDA in 2007 for oral anti-obesity applications
Reference Codes
[5AD]5mgCagrilintide
Long-Acting Amylin Analogue
- Amylin-pathway satiety — complementary to GLP-1 receptor agonists
- Long-acting acylated design supports convenient once-weekly dosing
Reference Codes
[CGL5]5mg[CGL10]10mgCagriSema
Amylin + GLP-1 Dual Agonist
- First combination to pair amylin and GLP-1 agonism in a single protocol
- Additive weight loss beyond what either pathway achieves alone
Reference Codes
[CS10]10mg (Cagri 5mg + Sema 5mg)5-Amino-1MQ
NNMT Inhibitor for Fat Metabolism
- Entirely distinct from GLP-1 and amylin pathways — a new axis for metabolic support
- Targets fat storage at the enzymatic level rather than appetite signaling
Reference Codes
[5AM]5mg[50AM]50mgResearch in Lean Body
CagriSema: Why the Amylin + GLP-1 Combination Is the Next Frontier in Metabolic Medicine
How combining amylin and GLP-1 pathways produces weight loss beyond what either achieves alone — and what the REDEFINE trials mean for metabolic science.
April 6, 2026 · 14 min read
Semaglutide: The GLP-1 Agonist That Changed Everything
Semaglutide research explained — STEP trial data, 16.9% weight loss, cardiovascular benefits, side effects, and how it compares to newer GLP-1 peptides.
April 4, 2026 · 16 min read
5-Amino-1MQ: A Completely Different Approach to Fat Metabolism
How inhibiting the NNMT enzyme shifts fat cells from storage mode to energy expenditure — without suppressing appetite or requiring injection.
March 27, 2026 · 11 min read
AOD-9604: The HGH Fragment Approach to Fat Loss
AOD-9604 mimics the fat-burning fragment of growth hormone without the side effects — what the Australian trials showed and how it compares to GLP-1 agonists.
March 19, 2026 · 11 min read
The GLP-1 Revolution: What the Science Actually Shows
Tirzepatide, Retatrutide, and the new generation of metabolic peptides — how they work, what the trials found, and why this changes everything.
March 14, 2026 · 14 min read
Retatrutide: The Triple Agonist That May Redefine Obesity Treatment
A comprehensive look at the first triple-receptor agonist in obesity research — how glucagon activation changes everything and what Phase 2 data reveals.
February 7, 2026 · 15 min read
Tirzepatide: Mounjaro, Zepbound, and the Dual Agonist Data
Everything the research shows about tirzepatide — SURMOUNT trial data, the GIP receptor debate, cardiovascular outcomes, and how it compares to semaglutide.
February 3, 2026 · 16 min read
All compound profiles are for educational reference only. This content does not constitute medical advice, diagnosis, or treatment recommendations. Consult a qualified healthcare provider.